Expression data for Sweet Syndrome patient and Healthy Controls

Acute febrile neutrophilic dermatosis (Sweet syndrome) is a potentially fatal multiorgan inflammatory disease characterized by fever, leukocytosis, and rash with a neutrophilic infiltrate. Disease pathophysiology remains elusive. Corticosteroids and steroid sparing agents remain mainstays of treatment, but refractory cases pose a clinical challenge. Transcriptomic profiling of a refractory Sweet syndrome patient will improve our understanding of pathophysiology of the disease and, ultimately wiil help us to find a guided therapy. We used microarray to perform molecular characterization of a particular refractory Sweet Syndrome patient and to identify altered pathways that may be targeted via currently available small molecular inhibitors. Lesional skin samples of the refractory pateint, Healthy-Controls and other Sweet Syndrome pateint samples were obtained as per study protocol that was approved by the Institutional Review Board of the University of Pennsylvania School of Medicine. Dermis was specifically isolated by laser capture microdissection from Formalin-Fixed paraffin embedded tissue section. It was followed by RNA extraction from dermal tissue and hybridization on Affymetrix microarrays.